Advancing Gene Therapy Approaches for Complement-Mediated Diseases to Achieve Long-Term Therapeutic Benefit with Reduced Dosing Requirements

• Evaluating the potential of gene therapies to provide sustained complement modulation
• Overcoming delivery, durability and safety challenges to maximize therapeutic benefit across systemic and tissue-specific diseases
• Sharing lessons learned from development pipelines to accelerate the translation of gene therapy approaches into approved treatments

Speakers:

Dennis Keefe

Chief Scientific Officer

Complement Therapeutics